Effect of house dust mite sublingual immunotherapy in patients with Atopic Dermatitis: a randomized, double-blind, placebo-controlled clinical trial

Abstract

the word ''peanut.'' These were manually reviewed for EPI documentation and other practice pattern characteristics. RESULTS: Of a total of 18,149 individuals, 152 (0.8%, mean age 6.4 months) had clinical documentation of EPI guidance (72% clinical note, 20% patient instructions, 5% both, 3% telephone note). EPI guidance was performed by 61 providers among 6 specialties (43% pediatrics, 40% family medicine, 15% allergy/immunology, 2% other) in 24 unique practices. Of those who received EPI guidance, the following comorbid diagnoses and/or characteristics were documented: 35% eczema, 11% egg allergy, 21% family history of food allergy, 31% topical corticosteroid use. Twenty percent were referred to an allergist for peanut allergy risk assessment and 12% had a peanut IgE obtained. CONCLUSIONS: Clinical documentation of EPI counseling is low. Further dissemination and implementation efforts are needed to encourage providers to prioritize EPI and increase standard utilization of consensus guidelines.

Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites

“…This last scale dominates as a parameter assessed in similar studies; however, the combination of EASI, %BSA and TMS scales seems more reliable and accurate [19][20][21]. In many studies, similar AD patients had the presence of allergic rhinitis with or without allergic asthma, which was significantly improved after HDM AIT [19][20][21]. These observations are consistent with the statements in the presented study.…”

“…Research by other authors also indicates that such desensitization may be effective in treating AD during 1 year using similar criteria of improvement by 50%, however, with the use of the SCORAD skin assessment scale [18]. This last scale dominates as a parameter assessed in similar studies; however, the combination of EASI, %BSA and TMS scales seems more reliable and accurate [19][20][21]. In many studies, similar AD patients had the presence of allergic rhinitis with or without allergic asthma, which was significantly improved after HDM AIT [19][20][21].…”

“…The obtained results indicate the effectiveness of HDM AIT in patients with advanced AD allergy, but mainly in patients with monosensitised HDM. Not many studies evaluate the effectiveness of HDM allergen injection immunotherapy in adult AD patients [18][19][20][21]. Zhou et al confirmed that 3 years of injection allergen immunotherapy to HDM significantly reduced the severity and pruritus of moderate-to-severe AD [19].…”

Sublingual immunotherapy for pediatric patients with mite allergies

“…1, a standard and validated measure that is widely used in Japan. [ 16 , 17 ] This tool includes a series of questions regarding the severity of multiple symptoms and the extent of its effects on several domains of QOL. It is preceded with a description that explains that the purpose of the survey is to determine to what extent the rhinitis interferes with their life and whether it would be improved by treatment; participants are told that they may find some of the questions difficult to answer, but they should just answer to the best of their ability.…”

“…Symptoms were evaluated using the Japanese rhino-conjunctivitis QOL questionnaire no. 1, a standard and validated measure that is widely used in Japan [16,17] . This tool includes a series of questions regarding the severity of multiple symptoms and the extent of its effects on several domains of QOL.…”